Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial
The secondary analysis of the STOPDAPT-3 trial demonstrated that among patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), there was no difference in cardiovascular events or BARC 3/5 bleeding events at one year between aspirin monotherapy and clopidogrel monotherapy initiated after one month of dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation, Dr. Hirotoshi Watanabe and colleagues, Hirakata Kohsai Hospital, Japan reported in the December 14 issue of the European Heart Journal.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
